🎉 Breaking News from Trutino Biosciences! 🎉 🚀 FDA IND Approval Secured! 🚀 What happens when a small but mighty start-up dreams big? Magic. The […]
Boehringer Ingelheim signed an option to acquire Trutino Biosciences Inc., a San Diego-based biotech company. Led by Phillip Kim, Ph.D., MBA, Founder and […]
Abstract Background An emerging class of new protease-activatable prodrugs designed to enhance on-target activity and reduce off-target toxicity are being actively developed. Cytokines […]
Abstract Recombinant IL-2 (aldesleukin) is a potent T cell proliferation and differentiation factor and is an approved immunotherapy for advanced melanoma and renal […]
Boehringer Ingelheim has struck a deal with Trutino Biosciences to develop three cytokine therapies. The deal tasks Trutino with applying a platform designed […]
This event is an exclusive global partnering and networking forum that brings together senior executives, bankers, venture capitalists, and business development professionals from […]
